Development and multi-observer validation of a histopathological scoring system for interstitial cystitis/bladder pain syndrome diagnosis - Summary - MDSpire
Advertisement
Creation and validation by multiple observers of a histopathological scoring system for diagnosing interstitial cystitis/bladder pain syndrome
To develop a histopathological scoring system for classifying bladder biopsies into BPS, HIC, and inflammatory non-HIC cystitis, and to validate its diagnostic performance and inter-observer reproducibility.
Approach:
Study Design: The study involved a cohort of patients diagnosed with BPS, HIC, and other cystitis types, with biopsies evaluated by multiple pathologists using a blinded approach.
Histopathological Scoring System: A five-feature scoring system was developed, assessing inflammation, plasma cell infiltration, eosinophil infiltration, tertiary lymphoid structures, and urothelial denudation.
Key Findings:
The histopathological scoring system demonstrated improved diagnostic consistency for distinguishing HIC from non-HIC cystitis.
Inter-observer reproducibility was validated among pathologists from different countries.
Interpretation:
The study supports the utility of a structured histopathological scoring system in enhancing the diagnostic accuracy for IC/BPS.
Limitations:
The study's findings may be limited by the specific patient population and the histological features evaluated.
Conclusion:
The developed scoring system may aid in the accurate classification of IC/BPS, potentially improving diagnostic practices.
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.
